Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-Tapering tight control rheumatoid arthritis care: Analyses of the DRESS study

Annals of the Rheumatic Diseases

Volumn 75, Issue 11, 2016, Pages 1939-1944

  Kievit, Wietske ^a   Van Herwaarden, Noortje ^b   Van Den Hoogen, Frank Hj ^a,b   Van Vollenhoven, Ronald F ^c   Bijlsma, Johannes Wj ^d   Van Den Bemt, Bart Jf ^a,b   Van Der Maas, Aatke ^b   Den Broeder, Alfons A ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SINT MAARTENSKLINIEK   (Netherlands)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Anti TNF; Economic Evaluations; Outcomes research; Rheumatoid Arthritis

Indexed keywords

ADALIMUMAB; ETANERCEPT; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DAS28; DISEASE ACTIVITY; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; AGED; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; MIDDLE AGED; NETHERLANDS;

ADALIMUMAB; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; ETANERCEPT; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; QUALITY-ADJUSTED LIFE YEARS;

EID: 84956656967     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208317     Document Type: Article

References (21)

1. Singh JA, Christensen R, Wells GA, et al. A network meta-Analysis of randomized controlled trials of biologics for rheumatoid arthritis: A Cochrane overview. CMAJ 2009;181:787-96
2. Graudal N, Jörgens G. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-Analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum 2010;62:2852-63
3. Huggett B. Public biotech 2012-The numbers. Nat Biotechnol 2013;31:697-703
4. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-Analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85
5. Bongartz T, Warren FC, Mines D, et al. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: A systematic review and individual patient data meta-Analysis of randomised controlled trials. Ann Rheum Dis 2009;68:1177-83
6. Askling J, Fored CM, Brandt L, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007;66:1339-44
7. Singh JA, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: A systematic review and meta-Analysis. Lancet 2015;386:258-65. http://dx.doi.org/10.1016/S0140-6736(14)61704-9 8 tarifs Dm. http://www.medicijnkosten.nl
8. Smolen JS, Emery P, Fleischmann R, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: The randomised controlled OPTIMA trial Lancet 2014;383:321-32
9. Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): A randomised controlled trial. Lancet 2013;381:918-29
10. van Herwaarden N, den Broeder AA, Jacobs W, et al. Down-Titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database Syst Rev 2014;9:CD010455
11. van Herwaarden N, van der Maas A, Minten MJ, et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. BMJ 2015;350:h1389
12. den Broeder AA, van Herwaarden N, van der Maas A, et al. Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study. BMC Musculoskelet Disord 2013;14:299
13. van der Maas A, Lie E, Christensen R, et al. Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: An OMERACT cohort validation study. Ann Rheum Dis 2013;72:1800-5
14. EuroQol G. EuroQol-A new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208
15. Lamers LM, McDonnell J, Stalmeier PF, et al. The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ 2006;15:1121-32
16. van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 2012;15:708-15
17. Hakkaart-van Roijen L, Tan SS, Bouwmans CAM. Handleiding voor kostenonderzoek, methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. College voor zorgverzekeringen. Geactualiseerde versie 2010
18. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programme. Third edition. Oxford: Oxford University Press, 2005
19. Solomon DH, Bitton A, Katz JN, et al. Review: Treat to target in rheumatoid arthritis: fact, fiction, or hypothesis? Value Health 2014; 66:775-82
20. van Hulst LT, Hulscher ME, van Riel PL. Achieving tight control in rheumatoid arthritis. Rheumatology (Oxford) 2011;50:1729-31
21. van der Maas A, Kievit W, van den Bemt BJ, et al. Down-Titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: An observational cohort study. Ann Rheum Dis 2012;71:1849-54